News
What affects the elimination of bisoprolol in diabetics and patients with acute coronary syndrome?
Beta-blockers are widely used to reduce cardiovascular (CV) risk in a number of diseases. However, information about the pharmacokinetics of these drugs is still far from complete. Two studies focused on the population pharmacokinetics (PopPK) of bisoprolol in patients with type 2 diabetes mellitus (DM2) and ischemic heart disease (IHD), and we summarize their conclusions.
What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran
Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The…
Interchangeability of Diosmin and Micronized Purified Flavonoid Fraction
Among the medicinal products reimbursed for chronic venous disease, those containing micronized…
Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?
A recently published study by a team of authors from several American institutions focused on…
Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk
Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum…
Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine…
Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and…
How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?
In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing…
Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer
In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the…
Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease
Are you applying the optimal approach to the treatment of chronic venous disease? What do the new…